![Michael Kranda](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Kranda
Direktor/Vorstandsmitglied bei
Nura, Inc.
Profil
Michael L.
Kranda is currently Director at Nura, Inc., Cumbre Pharmaceuticals, Inc., and Washington State Biotechnology Business Association.
Former roles include President & Chief Executive Officer at Anesiva, Inc.; Chief Executive Officer at Vaccinogen, Inc. from 2010 to 2012; Chief Executive Officer at Oxford GlycoSciences Plc in 2002; President, Chief Executive Officer & Director at BEAT BioTherapeutics Corp.; Chief Executive Officer at Twinstrand Biosciences, Inc.; Chief Executive Officer & Director at LifeSprout, Inc. from 2021 to 2023; Chairman at Raven Biotechnologies, Inc.; Independent Director at PTC Therapeutics, Inc. from 2013 to 2015; Director at BiPar Sciences, Inc.; President & Chief Operating Officer at Immunex Corp.
from 2009 to 2013; and Consultant at Cercano Management LLC.
Education includes undergraduate and MBAistration degrees from Michael G.
Foster School of Business.
Aktive Positionen von Michael Kranda
| Unternehmen | Position | Beginn |
|---|---|---|
Nura, Inc.
 Nura, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops pharmaceutical products | Direktor/Vorstandsmitglied | - |
Washington State Biotechnology Business Association | Direktor/Vorstandsmitglied | 15.09.2009 |
Cumbre Pharmaceuticals, Inc.
 Cumbre Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets anti-infective products | Direktor/Vorstandsmitglied | 15.09.2009 |
Ehemalige bekannte Positionen von Michael Kranda
| Unternehmen | Position | Ende |
|---|---|---|
LifeSprout, Inc.
 LifeSprout, Inc. Pharmaceuticals: MajorHealth Technology Develops synthetic soft tissue substitutes for reconstructive medicine | Vorstandsvorsitzender | 01.09.2023 |
| PTC THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 10.06.2015 |
| VACCINOGEN INC | Präsident | - |
Raven Biotechnologies, Inc.
 Raven Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Discovers and develops antibody therapeutics | Vorsitzender | 01.01.2008 |
Oxford GlycoSciences Plc
 Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Developes and manufactures novel products for the diagnosis and treatment of human disease | Präsident | 01.07.2002 |
Ausbildung von Michael Kranda
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
50
Beziehungen ersten Grades
15
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 15 |
|---|---|
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Manufactures, markets, and researches therapeutic products | Health Technology |
Anesiva, Inc.
 Anesiva, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for pain management | Health Technology |
PTC Therapeutics, Inc.
 PTC Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets clinically differentiated medicines for neurodegenerative diseases | Health Technology |
Nura, Inc.
Nura, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops pharmaceutical products | Health Technology |
Raven Biotechnologies, Inc.
Raven Biotechnologies, Inc. Miscellaneous Commercial ServicesCommercial Services Discovers and develops antibody therapeutics | Commercial Services |
BiPar Sciences, Inc.
 BiPar Sciences, Inc. Pharmaceuticals: MajorHealth Technology Develops and markets drugs for cancer patients | Health Technology |
Cumbre Pharmaceuticals, Inc.
Cumbre Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets anti-infective products | Health Technology |
Vaccinogen, Inc.
 Vaccinogen, Inc. BiotechnologyHealth Technology Develops vaccines for the treatment of cancer | Health Technology |
Oxford GlycoSciences Plc
Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Developes and manufactures novel products for the diagnosis and treatment of human disease | Health Technology |
Cercano Management LLC /Private Equity/
 Cercano Management LLC /Private Equity/ Investment ManagersFinance Cercano Management invests in companies located across the globe. The firm focuses on companies such as media conglomerates, energy minerals, financial services, healthcare services, life science and communication. It participates in leveraged buyouts, distressed/turnaround and early stage transactions with an investment size ranging from USD 10 to 100 million. | Finance |
Washington State Biotechnology Business Association | |
BEAT BioTherapeutics Corp.
 BEAT BioTherapeutics Corp. Pharmaceuticals: MajorHealth Technology Develops novel therapies for heart diseases | Health Technology |
Michael G. Foster School of Business
 Michael G. Foster School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Twinstrand Biosciences, Inc.
 Twinstrand Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Develops genomic technology and duplex sequencing technology to applications in clinical medicine & life sciences | Commercial Services |
LifeSprout, Inc.
LifeSprout, Inc. Pharmaceuticals: MajorHealth Technology Develops synthetic soft tissue substitutes for reconstructive medicine | Health Technology |
